Takeda Pharmaceutical (NYSE:TAK – Get Free Report) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday,Zacks.com reports.
A number of other equities research analysts have also recently commented on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Sunday. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, June 23rd. Finally, Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.
View Our Latest Report on Takeda Pharmaceutical
Takeda Pharmaceutical Stock Performance
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. Equities research analysts anticipate that Takeda Pharmaceutical will post 0.94 earnings per share for the current year.
Hedge Funds Weigh In On Takeda Pharmaceutical
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Private Trust Co. NA grew its position in shares of Takeda Pharmaceutical by 84.7% in the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares in the last quarter. SHP Wealth Management acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth about $42,000. Caitong International Asset Management Co. Ltd raised its position in shares of Takeda Pharmaceutical by 313.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after buying an additional 1,292 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
Read More
- Five stocks we like better than Takeda Pharmaceutical
- Short Squeeze Alert—Moderna Stock Surges on New Strategy
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
